Ascensia Spearheads $36 Million Investment in Wearable Glucose Sensor Startup Sava
Ascensia Diabetes Care has taken a leading role in a $36 million financing round for Sava, an emerging startup specializing in continuous monitoring technology for glucose and various other physiological biomarkers.
Exclusive Sales Agreement Established
Alongside the financial investment, Ascensia finalized an exclusive sales agreement with Sava. This commercial arrangement grants Ascensia specific distribution rights for the startup’s upcoming wearable sensor device once it becomes available on the market.
Expanding Continuous Monitoring Capabilities
Sava is currently developing a wearable device engineered to track glucose levels continuously. In addition to glucose tracking, the technology aims to monitor multiple biomarkers simultaneously, pointing toward broader applications in personal health tracking and remote patient monitoring.
- Ascensia led the $36 million funding round.
- An exclusive sales agreement was struck with Sava.
- The wearable device focuses on continuous glucose and biomarker monitoring.
Further details regarding the timeline for product development, clinical evaluations, or regulatory submissions were not disclosed in the initial announcement.
